Tools for Practice Outils pour la pratique

#104 Aldosterone antagonists in systolic heart failure – no longer an afterthought.

What is the role of aldosterone antagonists in patients with chronic systolic heart failure?

Aldosterone antagonists reduce mortality and hospitalizations in patients with congestive heart failure (Class II–IV). The benefit appears similar to β-blockers or ACE inhibitors. Close monitoring is required for those at risk of hyperkalemia.  

CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session

Two randomized controlled trials: 
  • RALES:1 1,663 patients with Class III–IV heart failure on ACE inhibitors and diuretics. Given spironolactone or placebo. At 24 months: 
    • Statistically significant reduction in: 
      • Mortality: spironolactone 35%, placebo 46%, Number Needed to Treat (NNT) 10. 
      • Cardiovascular hospitalization: 32% vs. 40%, NNT 12. 
    • Adverse events: 
      • Gynecomastia/breast pain: spironolactone 10%, placebo 1%, Number Needed to Harm (NNH) 11. 
      • Serious hyperkalemia (potassium ≥6 mmol/L): not statistically different. 
  • EMPHASIS-HF:2 2,737 patients with Class II heart failure with majority on ACE inhibitors, and β-blockers. Given eplerenone or placebo. At 21 months: 
    • Statistically significant reduction in: 
      • Mortality: eplerenone 13%, placebo 16%, NNT 34. 
      • Cardiovascular hospitalization: 22% vs. 29%, NNT 15. 
    • Adverse events: 
      • Hyperkalemia (>5.5 mmol/L) increased with eplerenone 12%, placebo 7%, NNH 22. 
      • No difference in gynecomastia or renal failure. 
Two meta-analyses found similar results.3,4 
  • Aldosterone antagonists compare favourably to other agents used in congestive heart failure whose relative risk reductions for mortality are: 
    • Aldosterone antagonists1,2 ~25%. 
    • β-blockers5 ~29%. 
    • ACE inhibitors6,7 ~23%. 
  • Aldosterone antagonists are prescribed at less than half the rate of β-blockers and ACE inhibitors, and represent the greatest potential for increased systolic heart failure survival.8 
  • Titration to target doses of ACE inhibitors and β-blockers before adding aldosterone antagonists has been advocated,9 however the rates/doses of these medications were quite different in RALES and EMPHASIS-HF, yet they had similar outcomes. 
  • There is no head-to-head trial of spironolactone vs. eplerenone. Spironolactone ($12/month) could be used first and, if gynecomastia/breast pain develop, switch to eplereonone ($100/month). 

Latest Tools for Practice
Derniers outils pour la pratique

#359 Topical corticosteroids for atopic dermatitis - More than skin deep

What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?
Read Lire 0.25 credits available Crédits disponibles

#358: Any berry good solutions to preventing UTIs: Cranberries?

Do cranberry products prevent recurrent urinary tract infections (UTIs)?
Read Lire 0.25 credits available Crédits disponibles

#357: Overcoming Resistance: Antipsychotics for difficult to treat depression

In patients with treatment-resistant depression, is adding an atypical antipsychotic to current therapy safe and effective?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session

  • Adrienne J Lindblad BSP ACPR PharmD
  • G. Michael Allan MD CCFP
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD

1. Pitt B, Zannad F, Remme WJ, et al. N Engl J Med. 1999; 341(10):709–17.

2. Zannad F, McMurray JJ, Krum H, et al. N Engl J Med. 2011; 364(1):11–21.

3. Ezekowitz JA, McAlister FA. Eur Heart J. 2009 Feb; 30(4):469–77.

4. Hu LJ, Chen YQ, Deng SB, et al. Br J Clin Pharmacol. 2013; 75(5):1202–12.

5. Bonet S, Agusti A, Arnau JM, et al. Arch Intern Med. 2000; 160:621–7.

6. Garg R, Yusuf S. JAMA. 1995 May 10; 273(18):1450–6.

7. Flather MD, Yusuf S, Kober L, et al. Lancet. 2000; 355:1575–81.

8. Fonarow GC, Yancy CW, Hernandez AF, et al. Am Heart J. 2011 Jun; 161(6):1024–30.

9. McKelvie RS, Moe GW, Ezekowitz JA, et al. Can J Cardiol. 2013; 29(2):168–81.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.